IQVIA (NYSE:IQV) PT Lowered to $260.00

IQVIA (NYSE:IQV) had its price objective decreased by research analysts at Barclays from $275.00 to $260.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “overweight” rating on the medical research company’s stock. Barclays‘s target price would indicate a potential upside of 11.56% from the stock’s previous close.

IQV has been the topic of several other reports. StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a research report on Monday. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. Truist Financial decreased their price objective on shares of IQVIA from $300.00 to $286.00 and set a “buy” rating on the stock in a research report on Monday. UBS Group upped their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Finally, JPMorgan Chase & Co. upped their price objective on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Four analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $267.87.

IQVIA Trading Up 0.0 %

Shares of IQV opened at $233.06 on Tuesday. The business’s 50-day moving average price is $239.14 and its 200-day moving average price is $231.33. IQVIA has a twelve month low of $167.42 and a twelve month high of $261.73. The stock has a market cap of $42.46 billion, a PE ratio of 31.84, a P/E/G ratio of 2.18 and a beta of 1.49. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion for the quarter, compared to analysts’ expectations of $3.79 billion. During the same period in the prior year, the business posted $2.22 earnings per share. The company’s revenue was up 2.3% on a year-over-year basis. On average, equities analysts forecast that IQVIA will post 10.25 EPS for the current fiscal year.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of the stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the sale, the insider now owns 19,536 shares of the company’s stock, valued at approximately $4,812,302.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.60% of the company’s stock.

Institutional Trading of IQVIA

Institutional investors have recently made changes to their positions in the stock. Centaurus Financial Inc. purchased a new stake in IQVIA in the fourth quarter worth $169,000. ICA Group Wealth Management LLC purchased a new stake in IQVIA in the fourth quarter worth $77,000. HighPoint Advisor Group LLC bought a new position in IQVIA in the fourth quarter worth $404,000. Nomura Holdings Inc. bought a new position in IQVIA in the fourth quarter worth $857,000. Finally, NBC Securities Inc. raised its holdings in IQVIA by 4.6% in the first quarter. NBC Securities Inc. now owns 2,919 shares of the medical research company’s stock worth $738,000 after purchasing an additional 128 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.